跳至主要内容
临床试验/NCT02627131
NCT02627131已完成2 期

Autologous Bone Marrow Stem Cell Therapy for Autism: An Open Label Uncontrolled Clinical Trial

Vinmec Healthcare System1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2014年4月1日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
24
试验地点
1
主要终点
Change in Total Score of Childhood Autism Rating Scale (CARS)

研究概览

简要总结

The aim of this study was to evaluate the safety and effectiveness of autologous bone marrow mononuclear stem cells in the management of autism.

详细描述

The aim of this study was to evaluate the safety and effectiveness of autologous bone marrow mononuclear stem cells in the management of autism of 24 patients at Vinmec International Hospital, Hanoi, Vietnam

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
3 Years 至 16 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Confirmed diagnosis of autism according to the Diagnostic and Statistical Manual-IV (DSM-IV) diagnostic criteria for autistic disorder

排除标准

  • Hydrocephalus with ventricular drain
  • Coagulation disorders
  • Allergy to anesthetic agents
  • Severe health conditions such as cancer, failure of heart, lung, liver or kidney
  • Active infections
  • Severe psychiatric disorders

结局指标

主要结局

Change in Total Score of Childhood Autism Rating Scale (CARS)

时间窗: 3 months and 6 months after transplantation

CARS

Number of adverse events

时间窗: Through study completion, an average of 6 months

Examples of adverse events to look for: vomiting, increased hyperactivity, fever, bleeding, hematoma, seizures and neurological deficits

次要结局

未报告次要终点

研究者

发起方
Vinmec Healthcare System
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验